Radient Pharmaceuticals Corporation (RPC) announced today the launch of the RPC Investor Channel -- a new and innovative video website developed to enhance communications and corporate access for key audiences interested in RPC.
Through this dynamic mode of communication everyone from existing and prospective shareholders, the broad investment community at large, healthcare professionals and their patients can learn about Radient Pharmaceuticals and its portfolio of in vitro diagnostic (IVD) cancer tests and products. In addition, financial Advisors have the ability to distribute RPC Investor Channel content to clients and securely track consumption when campaigning to clients about RPC, enhancing Radient's ability to scale consideration into new investor communities.
The site also features videos communicating RPC's business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC's portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure(R) IVD cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.
No comments:
Post a Comment